Neuropatogénesis inducida por el virus del sida: estrategias terapéuticas frente a la neurodegeneración inducida por la glucoproteína gp120/Tat en el sistema nervioso central

Merino, José J; Montes, M. Luisa; Blanco, Almudena; Bustos, María J; Oreja Guevara, Celia; Bayón, Carmen; Cuadrado, Antonio; Lubrini, Geny; Cambrón, Irene; Muñoz, Ainoa; Cebolla, Susana; Gutiérrez Fernández, Maria; Bernadino, José I; Arribas, José R; Fiala, Milan.
Rev. neurol. (Ed. impr.) ; 52(2): 101-111, 16 ene., 2011. tab, ilus
Artículo en Español | IBECS (España) | ID: ibc-86969

Documentos relacionados

  1. Schwann cell-derived CXCL1 contributes to human immunodeficiency virus type 1 gp120-induced neuropathic pain by modulating macrophage infiltration in mice.
  2. NMDA receptor antagonists engender neuroprotection against gp120-induced cognitive dysfunction in rats through modulation of PKR activation, oxidative stress, ER stress and IRE1α signal pathway.
  3. Wnt/<b>ß</b>-catenin signaling regulates brain-derived neurotrophic factor release from spinal microglia to mediate HIV<sub>1</sub> gp120-induced neuropathic pain.
  4. Morphine induces the release of CCL5 from astrocytes: potential neuroprotective mechanism against the HIV protein gp120.
  5. Thermal hyperalgesia and mechanical allodynia produced by intrathecal administration of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein, gp120.
  6. A rat model of human immunodeficiency virus 1 encephalopathy using envelope glycoprotein gp120 expression delivered by SV40 vectors.
  7. [HIV glycoprotein 120: possible etiological agent of AIDS-associated dementia].
  8. Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial.
  9. Neuronal injury due to HIV-1 envelope protein is blocked by anti-gp120 antibodies but not by anti-CD4 antibodies.
  10. Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand.